Imlunestrant is a next-generation, brain-penetrant, oral selective estrogen receptor degrader. In the phase III EMBER-3 trial, conducted in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer, imlunestrant demonstrated a significant progression-free survival benefit compared with standard endocrine therapy (standard of care; fulvestrant or exemestane) in patients harboring ESR1 mutations (ESR1m). Additionally, the combination of imlunestrant and abemaciclib improved outcomes compared with imlunestrant monotherapy, irrespective of ESR1m status.
ESMO Open published a clinical update in Oncology on 09 Apr 2026.
The item focuses on Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial.
Review the original article for the full source wording and details.